false
0001819411
0001819411
2024-01-31
2024-01-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
January 31, 2024
|
|
|
GAIN
THERAPEUTICS, INC. |
(Exact name of registrant as specified in its
charter) |
Delaware |
|
001-40237 |
|
85-1726310 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
4800
Montgomery Lane, Suite 220
Bethesda,
Maryland 20814
(Address of principal executive offices) (Zip
Code)
(301)
500-1556
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the
Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company x
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b)
of the Act:
Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
Common
Stock, par value $0.0001 |
GANX |
The
Nasdaq Stock
Market LLC |
Item 7.01 Regulation FD
On January 31, 2024, Gain Therapeutics, Inc. (the
“Company”) issued a press release containing a letter to the Company’s stockholders from its Chief Executive Officer,
Matthias Alder. A copy of the press release is furnished hereto as Exhibit 99.1 and incorporated herein by reference.
The information in this Item 7.01 of this Current
Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section,
nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as
shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
GAIN THERAPEUTICS, INC. |
|
|
Dated: January 31, 2024 |
By: |
/s/ C. Evan Ballantyne |
|
Name: |
C. Evan Ballantyne |
|
Title: |
Chief Financial Officer |
Exhibit 99.1
GAIN THERAPEUTICS’ CEO MATTHIAS ALDER ISSUES LETTER TO SHAREHOLDERS
AND PROVIDES OPERATIONAL UPDATE
BETHESDA, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics,
Inc. (Nasdaq: GANX) (“Gain,” or the “Company”), a biotechnology company leading the discovery and development
of allosteric small molecule therapies, today releases the following letter to stockholders from its President and Chief Executive Officer
Matthias Alder.
Dear Fellow Stockholders,
With the start of a new year, I want to take a moment to reflect on
Gain’s progress over the last 12 months and to share our strategy and plans for 2024.
Research and development of pharmaceutical products for the treatment
of neurodegenerative diseases has seen tremendous progress in recent years, with the approval of new drugs for the treatment of Alzheimer’s
disease, multiple sclerosis and ALS. The pharmaceutical industry is taking note as evidenced by the recent acquisition of Cerevel Therapeutics
for $8.7 billion by AbbVie, and the acquisition of preclinical-stage Caraway Therapeutics by Merck with an announced deal value of $610
million.
In Parkinson’s disease, the second most common neurodegenerative
disease after Alzheimer’s disease, new insights into the root cause of the disease have led to a number of drug candidates advancing
in clinical development, but there are no approved therapies available to patients that can slow or stop the progression of the disease.
At Gain, we seek to address this high unmet medical need with our clinical-stage lead drug candidate GT-02287, which we believe has disease-modifying
potential for the treatment of Parkinson’s disease and other neurodegenerative diseases.
Successful Transition to a Clinical-Stage Biotech Company
In 2023, we advanced GT-02287 through preclinical development and initiated
the company’s first clinical trial in September 2023 on time and on plan. The Phase 1 clinical trial is a single center, randomized,
double-blind, placebo-controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study to evaluate the safety and tolerability
of GT-02287 administered orally in healthy adults. The dose escalation of the SAD phase is underway, and the MAD phase of the study is
expected to begin in Q1 2024. The SAD/MAD part of the Phase 1 clinical trial is expected to be completed by mid-2024 with results expected
to be reported in the second half of the year.
In Q3 2024, we plan to start treatment of a cohort of 12-15 Parkinson’s
patients as an extension of the ongoing Phase 1 clinical trial to establish a biomarker-based clinical proof of concept, replicating the
effects of GT-02287 on biomarkers we have observed in our preclinical in vivo studies. We expect data from this study to be achieved in
late 2024 or early 2025 ahead of starting a Phase 2 clinical trial in the first half of 2025.
Cutting-Edge Science and Best-in-Class Preclinical Data Package
In 2023, we made several data presentations of results of our
GBA1 program in preclinical models of Parkinson’s disease and Alzheimer’s disease. For example, we presented new data
demonstrating a reduction of the plasma neurodegeneration biomarker NfL after administration of GT-02287 in a GBA1 Parkinson’s
disease model at the International Congress of Parkinson's Disease and Movement Disorders® last August. NfL is an emerging
biomarker of neurodegeneration that was recently accepted by the FDA as a surrogate endpoint in the agency’s accelerated
approval of a drug for the treatment of certain ALS patients. In that same preclinical model, GT-02287 also restored
β-glucocerebrosidase (GCase) enzymatic function, reduced aggregated α-synuclein, neuroinflammation and neuronal death,
increased dopamine levels and improved motor function.
We presented additional data on our allosteric GCase modulators at
the March 2023 International Conference on Alzheimer’s and Parkinson’s Diseases. In that poster presentation, we showed results
that we believe support the disease-modifying potential of allosteric GCase regulators for the treatment of Alzheimer’s disease.
Finally, we presented results of a preclinical model that we believe support the disease-modifying potential of a GCase-targeting small
molecule for neuronopathic Gaucher disease at last year’s 19th Annual WORLDSymposium.™ The data generated in an animal model
of neuronopathic Gaucher disease show that GT-02329 restores GCase activity, depletes accumulation of toxic lipid substrates, reduces
neuroinflammation, and improves neuromuscular function.
Additionally, we published data in PLOS ONE on our allosteric small
molecule modulators of the GLB1 enzyme showing significantly restored β-Gal function and reduced intracellular toxic substrates as
part of our program for GM1 gangliosidosis. These results were generated in collaboration with the Institute for Research in Biomedicine
in Bellinzona, Switzerland.
In 2024, we expect to present further data on GT-02287 from preclinical
models at scientific conferences, starting with the 20th Annual WORLDSymposium™ being held February 4-9, 2024, in San Diego, CA.
At that conference, we will present new in vitro and in vivo data that were accepted as a late-breaker abstract titled, “GT-02287,
a clinical stage GCase enhancer, displays neuroprotection and restores motor function in preclinical models of Parkinson’s disease
following delayed administration.” In addition, the abstract was selected for an oral presentation at the conference on February
9, 2024.
Based on the preclinical data we have generated with GT-02287 across
numerous in vitro and in vivo models of Parkinson’s disease, we believe that GT-02287 has a best-in-class preclinical profile with
evidence of improving the entire disease cascade caused by GCase dysfunction and offering the potential to slow or even stop the progression
of this devastating neurodegenerative disease.
Magellan™ Platform
During the course of 2023, we significantly upgraded our computational
drug discovery platform. The platform now provides for an integrated, efficient workflow of existing and newly added tools and programming
technologies that enable the identification of new binding sites on proteins and screening of the 50+ billion chemical spaces that have
become available through providers like Enamine. Over the last 18 months, we also expanded the application of the platform beyond its
original focus of enhancing and restoring enzyme function to new modalities that disrupt the function of target proteins.
Based on the added capabilities and expanded application, we feel
that the original platform name SEE-Tx (Site-specific Enzyme Enhancement Therapy) no longer adequately represents our platform
technology. Magellan, the name of our next-generation platform, reflects its enhanced capabilities that enable the exploration of
new protein biology and a vast chemical space to discover new allosteric small molecule therapies. Based on the unique combination
of physics-based models and integrated AI/ML-enhanced virtual screening capabilities, we believe Magellan is highly differentiated
in the field of computational drug discovery platforms and positions us to continue building our own pipeline of potential
first-in-class drug candidates. In addition, we are excited about the prospect of deploying Magellan in drug discovery
collaborations with academic institutions, biotechnology companies, CROs, and pharma companies, and will provide updates on our
progress in these efforts throughout 2024.
Cash Runway into 2025
In late November 2023, we completed a CMPO/PIPE financing that raised
gross proceeds of $10.1 million. Based on our operational plans, we are now positioned to fund our operations into 2025, which we expect
will enable the achievement of a biomarker-based clinical proof of concept of GT-02287 in the previously mentioned Phase 1 patient cohort.
In addition, we received grants totaling approximately $3.4 million during the year to fund R&D activities for our pipeline programs.
In 2024, we plan to continue tapping into grant opportunities to provide non-dilutive funding for our pipeline programs.
Strategic Partnering and Business Development
In 2023, we continued our active engagement with potential industry
partners for our pipeline programs and platform technology. Following the J.P. Morgan Healthcare conference in early January, I am optimistic
about our strategic partnering efforts, and we will continue to pursue opportunities for one or more of our R&D assets, whether for
our lead drug candidate GT-02287, our earlier pipeline programs, or the Magellan platform or a combination thereof. We believe that potential
transactions for any of our assets could provide significant non-dilutive funding and/or increase the inherent value of Gain by advancing
partnered programs through value inflection points.
Organizational Development
With the transition from a discovery and research-stage company to
a clinical-stage biotech company, we are continuously evaluating the organization and adding new skills required to achieve our goals
in the next 2-3 years while maintaining our focus on prudent cash management. Our new status as a clinical company has necessitated the
search for a Chief Medical Officer who will be charged with advancing the development of the clinical strategy for GT-02287 and leading
the clinical development team and related functions at Gain. We look forward to updating you once we have secured the appropriate candidate.
Also, individual career objectives can lead to changes in organizations. Unfortunately, we are saying goodbye to Dr. Xavi Barril, our
current Chief Technology Officer, who has been instrumental in guiding the evolution of our computational drug discovery platform. Xavi
is leaving the world of academia as a professor at the University of Barcelona and his part-time engagement with Gain to join a major
pharmaceutical company. As we wish him luck, the Magellan platform remains in good hands with an experienced team led by Dr. Elena Cubero,
who has been working with Xavi and the platform over the last 10 years.
Outlook for 2024
In 2024, we expect to achieve a series of important value inflection
points with Gain, which are summarized below:
Q1 2024:
| · | Poster and Platform Presentation of new data in preclinical model of Parkinson’s disease at WORLDSymposium |
| · | Start of MAD cohort in Phase 1 clinical trial with GT-02287 |
Q2 2024
| · | Completion of MAD cohort of Phase 1 clinical trial; potential for showing effect on GCase levels and activation |
Q3 2024
| · | Start of Parkinson’s patient cohort in Phase 1 clinical trial |
Q4 2024 / Q1 2025
| · | Completion of patient cohort; potential to show biomarker-based clinical proof of concept |
I look forward to updating you as we progress Gain’s business
and programs throughout this year and thank you for your continued support along the way to providing new treatments for debilitating
neurodegenerative diseases.
Sincerely,
Matthias Alder
President and CEO
Gain Therapeutics, Inc.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading
the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate GT-02287 for the treatment of
GBA1 Parkinson’s disease, is currently being evaluated in a Phase 1 clinical trial.
Leveraging AI-supported structural biology, proprietary algorithms
and supercomputer-powered physics-based models, the company’s Magellan™ discovery platform can identify novel allosteric binding
sites on disease-implicated proteins, pinpointing pockets that cannot be found or drugged with current technologies. Magellan is the next
generation of Gain’s original SEE-Tx® (Site-Directed Enzyme Enhancement Therapy) platform, which was enhanced and expanded with
new AI and machine-learning tools and virtual screening capabilities to access the emerging on-demand compound libraries covering vast
chemical spaces of over 50 billion compounds.
Gain’s unique approach enables the discovery of novel, allosteric
small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced platform, Gain is accelerating drug
discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative
diseases, rare genetic disorders and oncology. For more information, please visit GainTherapeutics.com and follow us on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release
other than statements of historical facts are “forward-looking statements”. In some cases, you can identify these
statements by forward-looking words such as "may," "might," "will," "should,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"goal, " "intend," "seek, " "potential" or "continue," the negative of these terms
and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all
forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to,
statements regarding: the development of the Company’s current or future product candidates including GT-02287; expectations
regarding the timing of results from a Phase 1 clinical trial for GT-02287 and the treatment of Parkinson’s patients in that
clinical trial; the potential therapeutic and clinical benefits of the Company’s product candidates including GT-02287; and
the execution of potential business development transactions and the effects thereof on the financial position of the Company. These
forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Each
of these forward-looking statements involves risks and uncertainties that could cause the Company’s preclinical and future
clinical development programs, future results or performance to differ materially from those expressed or implied by the
forward-looking statements. These statements are not historical facts but instead represent the Company's belief regarding future
results, many of which, by their nature, are inherently uncertain and outside the Company's control. Many factors may cause
differences between current expectations and actual results, including the impacts of the post-COVID-19 environment and other global
and macroeconomic conditions on the Company’s business; clinical trials and financial position; unexpected safety or efficacy
data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than
expected; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the
regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause the Company’s actual
results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the
section titled “Risk Factors,” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange
Commission on March 23, 2023 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission
from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made.
The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the
date on which they were made, except as required by law.
Contacts:
CORE IR
(516) 222-2560
ir@gaintherapeutics.com
v3.24.0.1
Cover
|
Jan. 31, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Jan. 31, 2024
|
Entity File Number |
001-40237
|
Entity Registrant Name |
GAIN
THERAPEUTICS, INC.
|
Entity Central Index Key |
0001819411
|
Entity Tax Identification Number |
85-1726310
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
4800
Montgomery Lane
|
Entity Address, Address Line Two |
Suite 220
|
Entity Address, City or Town |
Bethesda
|
Entity Address, State or Province |
MD
|
Entity Address, Postal Zip Code |
20814
|
City Area Code |
301
|
Local Phone Number |
500-1556
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, par value $0.0001
|
Trading Symbol |
GANX
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Gain Therapeutics (NASDAQ:GANX)
Historical Stock Chart
From Apr 2024 to May 2024
Gain Therapeutics (NASDAQ:GANX)
Historical Stock Chart
From May 2023 to May 2024